Definition And Epidemiology

  • Community acquired pneumonia represents an acute infection of the lung parenchyma.
  • It occurs in previously healthy children and is acquired outside of hospital settings.
  • The definition excludes children hospitalized within 14 days prior to symptom onset.
  • It excludes patients with immunodeficiency, severe malnutrition, and post-measles states.
  • It acts as the leading infectious cause of death globally in children under five years of age.
  • Mortality is closely linked to poverty, with over 99% of deaths occurring in low and middle-income nations.
  • Incidence has declined due to widespread use of antibiotics and vaccines.
  • Key protective vaccines include measles, pertussis, Haemophilus influenzae type b (Hib), and pneumococcal conjugate vaccine (PCV).

Pathogenesis And Anatomical Classification

  • The disease begins with the disruption of the complex lower respiratory ecosystem.
  • Pathogens typically enter via droplet infection.
  • Viral infections spread along the respiratory epithelium.
  • This leads to airway obstruction from swelling, abnormal secretions, and cellular debris.
  • Bacterial pathogens multiply directly within the alveoli.
  • This multiplication produces an inflammatory exudate leading to alveolar consolidation.
  • Anatomical classification includes lobar pneumonia, lobular pneumonia (bronchopneumonia), and interstitial pneumonia.

Etiological Profile

Age-Specific Pathogens

Age GroupFrequently Associated Pathogens
Neonates (<3 weeks)Group B Streptococcus, Escherichia coli, Gram-negative bacilli, Streptococcus pneumoniae, H. influenzae.
3 weeks to 3 monthsRespiratory syncytial virus, Rhinoviruses, Parainfluenza, S. pneumoniae, H. influenzae, Chlamydia trachomatis.
4 months to 4 yearsRespiratory syncytial virus, Rhinoviruses, Parainfluenza, Adenovirus, S. pneumoniae, H. influenzae, Mycoplasma pneumoniae, Group A Streptococcus.
$\ge$ 5 yearsM. pneumoniae, S. pneumoniae, Chlamydophila pneumoniae, H. influenzae, Influenza, COVID-19, Legionella pneumophila.

Exposure-Specific Pathogens

Exposure HistorySuspected Causative Agent
School dormitory or household outbreakM. pneumoniae, Neisseria meningitidis.
Contaminated aerosols (e.g., air coolers)Legionella species.
Goat hair, raw wool, animal hidesBacillus anthracis.
Bird contactChlamydophila psittaci.
Unpasteurized milk ingestionBrucellosis.

Clinical Presentation

Symptomatology And Signs

  • The illness often begins with an upper respiratory tract infection prodrome featuring rhinitis and cough.
  • Tachypnea serves as the most consistent and sensitive clinical manifestation.
  • Respiratory distress is evidenced by intercostal, subcostal, or suprasternal retractions.
  • Accessory muscle use, nasal flaring, and grunting may be present.
  • Auscultation frequently reveals crackles, wheezing, bronchial breathing, and diminished air entry.
  • Severe disease manifests with cyanosis, lethargy, tachycardia, and hypoxemia.
  • Patients may complain of abdominal pain due to referred pain from lower lobe involvement.

World Health Organization Tachypnea Criteria

Age GroupRespiratory Rate Cut-off
<2 months$\ge$ 60 breaths/minute.
2 months to 1 year$\ge$ 50 breaths/minute.
1 year to 5 years$\ge$ 40 breaths/minute.
>5 years$\ge$ 30 breaths/minute.

Differentiating Pneumonia Syndromes

Clinical FeatureViral PneumoniaTypical Bacterial PneumoniaAtypical Pneumonia
OnsetGradual, follows short upper respiratory tract infection.Sudden onset, rapid progression.Gradual onset.
FeverLow-grade.High-grade.Low-grade.
ToxicityLess toxic appearance.Highly toxic appearance.Non-toxic appearance (walking pneumonia).
AuscultationBilateral crackles and wheezing.Localized crackles, bronchial breathing.Diffuse crackles and wheezing.
Chest RadiographHyperinflation, bilateral interstitial infiltrates.Lobar consolidation.Diffuse lung involvement, bilateral perihilar streaks.

Triaging And Admission Criteria

  • Assess airway, breathing, and circulation upon arrival.
  • Hospitalization is indicated for any infant under three to six months of age.
  • Admit patients exhibiting hypoxemia, defined as oxygen saturation below 90-92% on room air.
  • Admit children demonstrating a toxic appearance, lethargy, or unconsciousness.
  • Severe respiratory distress, intermittent apnea, and grunting mandate admission.
  • Inability to tolerate oral fluids or feed, persistent vomiting, and severe dehydration require inpatient care.
  • Presence of complicated pneumonia, such as effusion, empyema, or abscess, requires admission.
  • Failure of outpatient therapy within 48 to 72 hours warrants hospitalization.

Diagnostic Evaluation

Laboratory Investigations

  • Community acquired pneumonia is primarily a clinical diagnosis.
  • Routine investigations are not required in an outpatient setting.
  • Hospitalized children require a complete blood count and blood cultures.
  • Viral infections typically show a normal or slightly elevated white blood cell count ($\le$ 20,000/mm³) with lymphocyte predominance.
  • Bacterial etiologies yield white blood cell counts of 15,000 to 40,000/mm³ with polymorphonuclear predominance.
  • Inflammatory markers like C-reactive protein and procalcitonin are elevated in bacterial disease and aid in monitoring treatment response.
  • Molecular multiplex reverse transcription polymerase chain reaction panels identify specific viral pathogens.
  • Isotype enzyme linked immunosorbent assay is superior to cold agglutinins for Mycoplasma detection.
  • Pulse oximetry remains essential for assessing severity and monitoring therapy.

Imaging Modalities

  • Routine chest radiographs are not required for uncomplicated outpatient cases.
  • Radiographs identify consolidation, atelectasis, hyperinflation, and pleural effusions.
  • The presence of pneumatoceles suggests Staphylococcus or Klebsiella infections.
  • Chest ultrasonography serves as a highly sensitive point of care tool to identify consolidations and effusions.
  • Contrast enhanced computed tomography provides superior imaging for identifying necrosis, abscesses, or underlying anatomical defects.

Differential Diagnosis

  • Recurrent pneumonia should be considered if there are $\ge$ 2 episodes per year or $\ge$ 3 episodes in a lifetime with radiographic clearing between episodes.
  • Hereditary causes include cystic fibrosis and sickle cell disease.
  • Immunodeficiency disorders like HIV, chronic granulomatous disease, and severe combined immunodeficiency present similarly.
  • Ciliary disorders such as primary ciliary dyskinesia should be excluded.
  • Anatomic malformations include pulmonary sequestration and congenital pulmonary airway malformations.
  • Acquired causes include retained foreign bodies and severe gastroesophageal reflux disease.

Management Strategies

Outpatient Pharmacotherapy

Age GroupFirst-Line PharmacotherapySecond-Line / Alternative TherapyNotes
3 months to 5 yearsOral Amoxicillin (40-50 mg/kg/day divided twice daily)Co-amoxiclav, Cefpodoxime, or CefuroximeDose can be increased to 80-90 mg/kg/day if there is a high risk of penicillin-resistant pneumococci.
Over 5 yearsSimilar first-line regimens as aboveMacrolides (e.g., Azithromycin 10 mg/kg/day once daily)Macrolides are indicated for suspected atypical organisms.

Inpatient Pharmacotherapy

Age Group / ConditionParenteral Pharmacotherapy RegimenAdditional Clinical Notes
Infants under 3 monthsCefotaxime +/- Gentamicin/Amikacin, or CeftriaxoneRequires admission. If Staphylococcus aureus is suspected, add Cloxacillin or Vancomycin/Linezolid.
3 months to 5 yearsAmpicillin, Ceftriaxone, or Cefotaxime
Over 5 yearsAmpicillin, Ceftriaxone, or Macrolides
Viral PneumoniaSymptomatic and supportive carePurely supportive.
Suspected H1N1 InfluenzaOseltamivirIndicated if initiated within 3 days of symptom onset.

General Inpatient Protocol

ProtocolDetails
Transition to Oral AntibioticsOccurs upon clinical improvement and once the child is afebrile for 48 to 72 hours.
Duration of TherapyTotal duration of antimicrobial therapy generally spans 7 to 10 days for uncomplicated cases.

Supportive Care

  • Provide continuous oxygen therapy to maintain oxygen saturation above 94%.
  • Administer intravenous fluids to address severe distress or clinical dehydration.
  • Use Paracetamol as an antipyretic for fever control and comfort.
  • Provide advanced respiratory support such as bubble continuous positive airway pressure, high flow nasal cannula, or mechanical ventilation for impending respiratory failure.

Complications

  • Local and intrathoracic complications include pleural effusion, empyema, and pyopneumothorax.
  • Pneumatocele formation, lung abscess, necrotizing pneumonia, and bronchopleural fistulas may occur.
  • Systemic and metastatic complications encompass bacteremia and overwhelming sepsis.
  • Infection may seed to remote locations causing purulent pericarditis, meningitis, suppurative arthritis, and osteomyelitis.

Prevention Strategies

  • Timely immunization remains the most effective preventive measure.
  • Ensure administration of pneumococcal conjugate vaccine, Haemophilus influenzae type b vaccine, influenza vaccine, measles vaccine, and pertussis vaccine.
  • High-risk infants may receive Nirsevimab for passive immunoprophylaxis against respiratory syncytial virus.
  • Environmental measures include promoting exclusive breastfeeding and preventing exposure to passive tobacco smoke.
  • Addressing household crowding and providing adequate zinc supplementation significantly mitigates disease risk.